The detail that quietly reshapes the 4D-150 story isn’t the enrollment headline — it’s that 4DMT completed randomization of all 523 participants in 4FRONT-1 roughly a month after finishing enrollment, a compression that signals genuine site readiness rather than the prolonged screen-failure attrition that stalls most large retinal trials. With topline data now locked to H1 2027, the program has a credible 12-month runway to a pivotal readout, and $458 million in cash buys time well past that event into the second half of 2028.
The more structurally interesting question sits inside the 4FRONT-2 timeline. Global enrollment is expected to complete in H2 2026, with topline data a full six months behind 4FRONT-1 in H2 2027. That stagger is deliberate — it mirrors a two-region regulatory strategy, preserving a North American package for an initial BLA while building a simultaneous global dossier for ex-U.S. submissions. What the company will need to show before either readout lands is whether the Phase 2b PRISM 2-year data, due at a scientific conference in Q3 2026, holds the durability signal that justified the Phase 3 bet in the first place. The “recently diagnosed subgroup” framing in the PRISM presentation is a direct acknowledgment that the 4FRONT populations skew earlier disease, and any erosion of the VEGF-suppression signal in that subgroup would reprice the trial’s probability of success immediately.
R&D spend jumped to $65 million in Q1 2026 from $40.7 million a year ago, almost entirely driven by 4FRONT execution. That burn rate puts full-year R&D well above $250 million before accounting for the DME Phase 3, which is now expected to initiate in Q3 2026. Otsuka’s cost-sharing contribution is real but modest — $3 million in collaboration revenue in Q1 — meaning 4DMT is carrying the operational weight while preserving milestone optionality. The geographic atrophy program in 4D-175 is effectively parked, and cystic fibrosis through 4D-710 won’t generate a program update until H2 2026, so capital allocation is almost entirely a wet AMD and DME story for the next 18 months.
The single data event that determines everything else is the PRISM 2-year durability readout in Q3 2026. If sustained VEGF suppression holds at 24 months in the recently-diagnosed population, 4FRONT-1’s H1 2027 topline becomes a formality worth watching closely; if it doesn’t, the Phase 3 design assumptions face a serious challenge before the pivotal data even arrive.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
